Genocea Reports Interim Immunogenicity Data From GEN-009 Neoantigen Vaccine Phase 1/2a Trial: 'Post-vaccination immune responses detected to 93% of vaccine neoantigens in first three patients analyzed'
Benzinga Newsdesk